We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-7.49%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.45B
AUM Growth
-$331M
Cap. Flow
-$447M
Cap. Flow %
-18.22%
Top 10 Hldgs %
43.96%
Holding
111
New
16
Increased
20
Reduced
24
Closed
16

Top Buys

Rank Stock Value
1
MIRM icon
Mirum Pharmaceuticals
MIRM
+$42.3M
2
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$42.2M
3
AERI
Aerie Pharmaceuticals
AERI
+$35.2M
4
SWTX
SpringWorks Therapeutics
SWTX
+$24.8M
5
CNC icon
Centene
CNC
+$20.3M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$27.7M
2
IMMU
Immunomedics Inc
IMMU
+$26M
3
STAA icon
STAAR Surgical
STAA
+$25.8M
4
NVRO
NEVRO CORP.
NVRO
+$25M
5
NVTA
Invitae Corporation
NVTA
+$23.4M

Sector Composition

Rank Sector Weight
1 Healthcare 71.17%
2 Financials 0.3%
3 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KNSA icon
51
Kiniksa Pharmaceuticals
KNSA
$4.81B
$10.8M 0.44%
1,274,086
-36,173
-3% -$400K
KALV
52
DELISTED
KalVista Pharmaceuticals
KALV
$10.3M 0.42%
890,668
-327,000
-27% -$5.28M
MNK
53
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$10.1M 0.41%
4,191,327
+13,108
+0.3% +$67K
INGN icon
54
Inogen
INGN
$173M
$9.18M 0.37%
+191,660
New +$10M
GH icon
55
Guardant Health
GH
$19.6B
$8.04M 0.33%
+126,000
New +$11.1M
BCRX icon
56
BioCryst Pharmaceuticals
BCRX
$2.32B
$7.95M 0.32%
2,774,643
-3,518,337
-56% -$10.9M
EHTH icon
57
eHealth
EHTH
$45.1M
$7.35M 0.3%
110,000
-200,900
-65% -$18.1M
ATRC icon
58
AtriCure
ATRC
$1.76B
$7.3M 0.3%
+292,777
New +$8.36M
XFOR icon
59
X4 Pharmaceuticals
XFOR
$347M
$7.17M 0.29%
18,791
-42
-0.2% -$16.6K
AIMT
60
DELISTED
Aimmune Therapeutics
AIMT
$7.11M 0.29%
+339,480
New +$6.93M
TECX
61
Tectonic Therapeutic
TECX
$605M
$7.06M 0.29%
+41,667
New +$9.43M
BBIO icon
62
BridgeBio Pharma
BBIO
$15.8B
$6.23M 0.25%
290,000
– –
MDCO
63
PUT
DELISTED
Medicines Co
MDCO
$5M 0.2%
100,000
– –
PRVB
64
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$4.95M 0.2%
+725,000
New +$7.33M
ABMD
65
DELISTED
Abiomed Inc
ABMD
$4.91M 0.2%
+27,600
New +$5.97M
FTSV
66
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$4.82M 0.2%
+750,000
New +$6.16M
IGMS
67
DELISTED
IGM Biosciences
IGMS
$4.44M 0.18%
+250,000
New +$5.05M
ALIM
68
DELISTED
Alimera Sciences
ALIM
$4M 0.16%
470,840
+67,311
+17% +$611K
SYRE icon
69
Spyre Therapeutics
SYRE
$8.45B
$3.85M 0.16%
20,002
– –
IDYA icon
70
IDEAYA Biosciences
IDYA
$3.41B
$3.81M 0.16%
422,974
-2,026
-0.5% -$15.5K
HARP
71
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$3.61M 0.15%
26,450
-2,050
-7% -$288K
BDSI
72
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$3.44M 0.14%
816,096
– –
MOR
73
DELISTED
MorphoSys AG American Depositary Shares
MOR
$3.43M 0.14%
124,701
-475,299
-79% -$13.6M
STIM icon
74
Neuronetics
STIM
$141M
$2.82M 0.12%
339,512
+180,512
+114% +$1.97M
ITMR
75
DELISTED
Itamar Medical Ltd. American Depository Shares
ITMR
$2.75M 0.11%
314,136
– –
1 2
3
4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q3 2019 Portfolio in Review

As of Q3 2019, Deerfield Management held 111 positions worth $2.45B, down 12% from $2.78B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Deerfield Management withdrew a net $447M in Q3 2019, closing 16 positions and reducing 24 holdings. Its most notable exit was Natera, an estimated $27.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 68% a quarter earlier, followed by Financials and Consumer Discretionary.

Against the trend, Deerfield Management opened a new position in Mirum Pharmaceuticals worth $34.7M.

  • Deerfield Management's largest Q3 2019 buy was Mirum Pharmaceuticals: 3,448,912 shares worth $34.7M.
  • Deerfield Management added most to Rhythm Pharmaceuticals in Q3 2019, an estimated $42.2M increase.
  • Deerfield Management's biggest Q3 2019 reduction was Immunomedics Inc, cutting an estimated $26M.
  • Deerfield Management fully exited Natera in Q3 2019, selling an estimated $27.7M.
  • Deerfield Management's ten largest holdings make up 44% of its $2.45B portfolio in Q3 2019.
  • Deerfield Management opened 16 new positions and closed 16 in Q3 2019.
  • Deerfield Management's portfolio value fell 12% quarter-over-quarter to $2.45B.

Based on Deerfield Management's 13F filing for Q3 2019, filed 14 Nov 2019.